Patent ID: 11957751
Assignee: LUDWIG INSTITUTE FOR CANCER RESEARCH LTD
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C  B  G | IPC A  B  C  G

Claim 7:
8. The method of claim 1 which comprises further administering one or more other agents or therapeutics, wherein the one or more other agents or therapeutics are immune modulators and wherein the immune modulators are selected from indoleamine-2,3-dioxygenase (IDO), tryptophan-2,3-dioxygenase (TDO), α-galactosyl ceramide or α-galactosyl ceramide analog threitolceramide (IMM47), toll-like receptor (TLR) ligands, inducible T-cell co-stimulator (iCOS), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD1), PD1 ligand, OX40(CD134), OX40 ligand, lymphocyte-activation gene 3 (Lag3), glucocorticoid-induced TNFR-related protein (GUM), GITR ligand, interleukins and tumor necrosis factor (TNF).